Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)
16 October 2021 - 01:15AM
Edgar (US Regulatory)
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b)
OF THE SECURITIES EXCHANGE ACT OF 1934.
| |
Commission File Number
001-06571 |
|
Issuer: | Merck & Co., Inc. |
Exchange: | NEW YORK STOCK EXCHANGE LLC |
(Exact name of Issuer as specified in its charter, and name of
Exchange where security is listed and/or registered)
|
|
Address: | 2000 Galloping Hill Road Kenilworth, NEW JERSEY 07033 |
Telephone number: | (908) 740-4000 |
(Address, including zip code, and telephone number, including area code, of Issuer's
principal executive offices)
|
|
1.125% Notes due 2021 |
(Description of class of securities)
|
|
Please place an X in the box to designate the rule provision relied upon to strike
the class of securities from listing and registration:
|
o 17 CFR 240.12d2-2(a)(1) |
x 17 CFR 240.12d2-2(a)(2) |
o 17 CFR 240.12d2-2(a)(3) |
o 17 CFR 240.12d2-2(a)(4) |
o
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
1 |
o
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
|
|
Pursuant to the requirements for the Securities Exchange Act of 1934,
NEW YORK STOCK EXCHANGE LLC
certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing the Form 25 and has caused this notification to be
signed on its behalf by the undersigned duly authorized person.
|
|
2021-10-15 | By | Lauren Frawley | | Regulation Analyst |
Date
| | Name | | Title |
|
1 |
Form 25 and attached Notice will be considered compliance with the provisions of
17 CFR 240.19d-1 as applicable. See General Instructions.
Merck (NYSE:MRK) Historical Stock Chart From Mar 2024 to Mar 2024
Merck (NYSE:MRK) Historical Stock Chart From Mar 2023 to Mar 2024
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults Thursday 28 March 2024 (1 day ago) • Business Wire |
GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News Wednesday 27 March 2024 (2 days ago) • IH Market News |
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) Wednesday 27 March 2024 (3 days ago) • Business Wire |
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer Thursday 21 March 2024 (1 week ago) • Business Wire |
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults Wednesday 20 March 2024 (1 week ago) • Business Wire |
FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform Saturday 16 March 2024 (2 weeks ago) • PR Newswire (US) |
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer Friday 15 March 2024 (2 weeks ago) • Business Wire |
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9 Wednesday 13 March 2024 (2 weeks ago) • Business Wire |
Merck Completes Acquisition of Harpoon Therapeutics, Inc. Monday 11 March 2024 (3 weeks ago) • Business Wire |
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 Thursday 7 March 2024 (3 weeks ago) • Business Wire |
Futures Pointing To Continued Weakness On Wall Street Wednesday 6 March 2024 (3 weeks ago) • IH Market News |
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference Tuesday 5 March 2024 (3 weeks ago) • Business Wire |
More Merck & Co., Inc. News Articles
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|